In this commentary, I review recent advances in Alport syndrome genetics, diagnostics, and therapeutics. I also offer some opinions regarding strategies to optimize the early identification of affected individuals to promote early therapeutic intervention.
Keywords: Alport syndrome; COL4A3; COL4A4; COL4A5; collagen IV alpha-345 network; end-stage renal disease.